Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2020

September 2020 | 209 pages | ID: E9358B56CBCEN
Global Markets Direct

Abstracts

Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2020, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.
Epstein-Barr virus (EBV) or human herpes virus 4 virus is a member of the Herpesviridae family. It is one of the most common human viruses to cause cancer in humans and is associated with a wide range of human cancers originating from epithelial cells, lymphocytes and mesenchymal cells. It spreads most commonly through bodily fluids. It can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash. Treatment includes over-the-counter pain and fever medications to get relief from the symptoms of the disease.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 3, 8, 5 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 9, 4, 6 and 4 molecules, respectively.
Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Epstein-Barr Virus Infections - Overview
Epstein-Barr Virus Infections - Therapeutics Development
Epstein-Barr Virus Infections - Therapeutics Assessment
Epstein-Barr Virus Infections - Companies Involved in Therapeutics Development
Epstein-Barr Virus Infections - Drug Profiles
Epstein-Barr Virus Infections - Dormant Projects
Epstein-Barr Virus Infections - Discontinued Products
Epstein-Barr Virus Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Advenchen Laboratories LLC, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by AlloVir Inc, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Boryung ViGenCell Inc, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Bristol-Myers Squibb Co, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Children's National Research Institute, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by China Immunotech Co Ltd, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Cullinan Oncology LLC, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Eutilex Co Ltd, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Galenbio Ltd, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Dormant Projects, H2 2020
Epstein-Barr Virus (HHV-4) Infections - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Advenchen Laboratories LLC
AlloVir Inc
Atara Biotherapeutics Inc
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Children's National Research Institute
China Immunotech Co Ltd
Cullinan Oncology LLC
Eutilex Co Ltd
Galenbio Ltd
Geneius Biotechnology Inc
Genocea Biosciences Inc
Good T Cells Inc
Immunotech Biopharm Ltd
Incyte Corp
Karyopharm Therapeutics Inc
Lion TCR Pte Ltd
Moderna Inc
Omeros Corp
Oxford Vacmedix UK Ltd
Replicate Bioscience Inc
Savoy Pharmaceuticals Inc
Viracta Therapeutics Inc
Vironika LLC
ViroStatics SRL